iRhythm Beats Q2 Revenue, Raises Guidance, and Acquires Vital Connect for $287.5M
IRTC sits 27% above its 52-week low of $100.846 on elevated volume (2.1× avg).
Summary
iRhythm delivered a strong Q2 with revenue of $224.2M, beating the $219.3M consensus, and swung to an adjusted net income of $19.3M from a loss a year ago. The company raised its full-year 2026 revenue guidance to $880M-$890M and expects adjusted EBITDA margins of 13%-14%, signaling confidence in sustained volume growth and margin expansion. In a strategic move, iRhythm announced the acquisition of Vital Connect for $287.5M to broaden its cardiac monitoring platform. This follows a cybersecurity incident disclosed in June and a $45M securities litigation settlement in May, but the operational momentum appears intact. The stock, trading at 190x forward earnings, reflects high growth expectations that these results reinforce.
At the time of this announcement, IRTC was trading at $128.12 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.2B. The 52-week trading range was $100.85 to $212.00. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Reuters.